Taiwan COVID vaccine maker to apply for EUA after promising Phase II trial results
06/10/2021 05:39 PM
Medigen Vaccine Biologics Corp., a Taiwan-based biopharmaceutical company, said Thursday that it would seek an Emergency Use Authorization (EUA) for its COVID-19 vaccine candidate after unblinding the results of its Phase II clinical trials.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
Typhoon, rain cause over NT$2.6 billion in agricultural losses in Taiwan
07/14/2025 10:33 PM - Society
Warmth in the dark: Anonymous man shows respect to Taipower workers
07/14/2025 10:28 PM - Sports
Taiwan billiards star Chang Jung-lin dies suddenly aged 40
07/14/2025 09:54 PM - Business
Taiwan's stabilization fund to continue stock market intervention
07/14/2025 09:18 PM - Politics
Urban resilience drills begin Tuesday
07/14/2025 09:08 PM